ClinicalTrials.gg
RecruitingNCT06007222Updated Sep 23, 2024

Non-antithrombotic Therapy After Transcatheter Aortic Valve Implantation Trial

A Phase 4 interventional study of Aspirin group and Non-antithrombotic group in Aortic Stenosis, TAVI(Transcatheter Aortic Valve Implantation) and Aspirin, sponsored by OCEAN-SHD Study Group. Recruiting at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-09-23.

Sponsored by OCEAN-SHD Study Group · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Apr 2023, registered Aug 2023).
  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Aortic Valve Stenosis with a site in Japan — 4 open to participants now, 7 under way, none of them phase 3. Aortic Valve Stenosis · Japan.

Planned enrollment
5th of 15
400 · median 64
Started
2023
the only one that year
Phase 4
2 of 19
1 open now
Registered
17th of 19
by date
Lead sponsor
1 of 19
OCEAN-SHD Study Group

Among the 19 studies in Aortic Valve Stenosis with a site in Japan, this one is the 5th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2023, is one of 2 in phase 4, and was the 17th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

4 of the 19 studies in Aortic Valve Stenosis with a site in Japan are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Aortic Valve Stenosis with a site in Japan, or all of them as a file.
02

Study summary

Aspirin group: Aspirin 100mg will be started within 24 hours after randomization, and continued aspirin 100mg/day the end of the study period.

Non-antithrombotic group: No antithrombotic agents will be administered after randomization until the end of the study period.

03

Conditions studied

  • Aortic Stenosis
  • TAVI(Transcatheter Aortic Valve Implantation)
  • Aspirin
  • DAPT(Dual Antiplatelet Therapy)
  • SAPT(Single Antiplatelet Therapy)
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who underwent transfemoral TAVI for aortic stenosis
  2. Patients aged 20 years or older at the time of
  3. Patients who have a thorough understanding of the subject of the study and who have agreed in writing to participate in the study

Exclusion criteria

Exclusion Criteria:

  1. Those with perioperative complications at the time of TAVI (conversion to open heart surgery, coronary artery occlusion, annulus rupture, cardiac tamponade, vascular dissection, cerebral infarction/cerebral hemorrhage, new atrial fibrillation, new atrioventricular block)
  2. Individuals requiring antiplatelet agents for reasons other than TAVI (history of myocardial infraction, history of PCI(Percutaneous Coronary Intervention), history of EVT(EndoVascular Treatment), history of cerebral infraction and transient ischaemic stroke, with significant coronary artery narrowing, with high-grade carotid artery narrowing, and others judged as requiring antiplatelet therapy by the chief researcher or a sub-investigator)
  3. Patients requiring oral anticoagulants (patients with atrial fibrillation, history of pulmonary embolism or deep venous thrombosis, and other patients who are deemed to require anticoagulation therapy by the investigator or coinvestigator)
  4. Patients with (estimated Glomerular Filtration Rate) \<30 and patients on hemodialysis/peritoneal dialysis.
  5. Patients with a history of valve replacement in the heart valves.
  6. Patients who are pregnant, have , wish to become pregnant, or are breastfeeding.
  7. Patients who have a concomitant medical illness associated with expected survival less than one year.
  8. Patients who have the for aspirin.
  9. Patients with a diagnosis of severe allergy to aspirin or a history of .
  10. Patients requiring a legally acceptable representative, patients unable to obtain written , or patients unable to understand the outline or purpose of the study.
  11. Other patients for whom the principal investigator or the coinvestigator judges the participation in the study inappropriate.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Active comparator
    Aspirin group

    Aspirin 100mg will be started within 24 hours after randomization, and continued aspirin 100mg/day the end of the study period.

    Drug: Aspirin group

  • Experimental
    Non-antithrombotic group

    No antithrombotic agents will be administered after randomization until the end of the study period.

    Drug: Non-antithrombotic group

Interventions

  • DrugAspirinStudies of AspirinAspirin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Aspirin 100mg will be started within 24 hours after randomization, and continued aspirin 100mg/day the end of the study period.

  • DrugNon-antithrombotic group

    No antithrombotic agents will be administered after randomization until the end of the study period.

06

What researchers measure

Primary outcomes

  1. Primary endpoint

    Composite endpoint consisting of all-cause deaths, myocardial infarction, stroke from any cause and bleeding from randomization to end of study The outcomes of this study will comply with the Valve Academic Research Consortium 3 (VARC 3). VARC 3 Type 1, Type 2, Type 3, and Type 4 bleeding are all included as bleeding. In this study, the study subjects will be randomized after it has been confirmed that there were no perioperative complications, so it is essentially assumed that there will be no procedure-related bleeding. Surviving subjects for whom the event does not occur will be censored as of the date the study treatment is discontinued or as of the last confirmed date of survival.

    Time frame: minimum 2 years, maximum 3 years of follow-up

Secondary outcomes

  1. Key Secondary endpoint

    Bleeding Events from Randomization to Study End. Cardiovascular adverse events from randomization until the end of the study (composite endpoint comprised of cardiovascular death, myocardial infarction, or CVA). The definition of censoring for survival time analysis is the same as that used for the primary endpoint.

    Time frame: minimum 1 year, maximum 3 years of follow-up

07

Study locations

1 of 1 sites recruiting
  • Keio University Hospital
    Shinjuku, Tokyo 160-8582, Japan
    Recruiting
    • Kentaro Hayashida · Contactkhayashida.z6@keio.jp · 03-5843-6702
    • Masanori Yamamoto · Contact
    • Tetsuro Shimura · Contact
    • Takahiro Tokuda · Contact
    • Masahiko Noguchi · Contact
    • Hiroshi Ueno · Contact
    • Hiroto Suzuyama · Contact
    • Masahiko Asami · Contact
    • Shinichi Shirai · Contact
    • Yusuke Watanabe · Contact
    • Kouhei Yamaguchi · Contact
    • Norio Tada · Contact
    • Futoshi Yamanaka · Contact
    • Yohei Ohno · Contact
    • Masaki Izumo · Contact
    • Kazumasa Yamasaki · Contact
    • Hidetaka Nishina · Contact
    • Yasushi Fuku · Contact
    • Gaku Nakazawa · Contact
    • Fumiaki Yashima · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Dec 2026, 44 months after the start.

Of 25 phase 4 interventional studies under Aortic Valve Stenosis, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 70. This study's planned 44 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2023
First posted
Aug 23, 2023
StartActual
Apr 6, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Sep 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06007222
Lead sponsor
OCEAN-SHD Study Group
Responsible party
Sponsor
First posted
Aug 23, 2023
Start date
Apr 6, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 23, 2024

Study contacts

Yosuke Sawa
Contact
sawa.yosuke872@eps.co.jp
+81-70-2492-4466
Yosuke Sawa
study director · EPS Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion